RayKnowChina Research Map
Shortlist0

ShanghaiShanghai Jiao Tong University School of Medicine

Shanghai Children's Medical Center

上海交通大学医学院附属上海儿童医学中心

Listed for 17 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanghai Children's Medical Center

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatoblastoma肝母细胞瘤17 papers led1 open trial led
  2. Osteosarcoma骨肉瘤0 papers led
  3. Neuroblastoma神经母细胞瘤11 papers led
  4. Ewing sarcoma尤文肉瘤0 papers led
  5. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病8 papers led1 open trial led
  6. Aplastic anaemia再生障碍性贫血5 papers led
  7. Beta thalassaemiaβ 地中海贫血0 papers led
  8. Fanconi anaemia范可尼贫血2 papers led
  9. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  10. Fabry disease法布雷病0 papers led
  11. Pompe disease庞贝病0 papers led
  12. Duchenne muscular dystrophy杜氏肌营养不良0 papers led2 open trials led
  13. IgA nephropathyIgA 肾病3 papers led
  14. Gaucher disease戈谢病0 papers led
  15. Congenital diaphragmatic hernia先天性膈疝2 papers led
  16. Hirschsprung disease先天性巨结肠2 papers led
  17. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Multiple myeloma, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Behçet disease, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatoblastoma

肝母细胞瘤

Led 17 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 11.0%.

Papers led
17
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 4420232024: 4420242025: 882025

8 hospitals in Shanghai for hepatoblastoma88 hospitals in China for hepatoblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04478292

    Age Not stated to 18 years (registered criteria)

    Led by Shanghai Children's Medical CenterShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led17
  1. Malignant Hepatoblast-Like Cells Sustain Stemness via IGF2-Dependent Cholesterol Accumulation in Hepatoblastoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Hepatoblastoma regional trends: dynamic SDI & joinpoint regression analysis.2025BMC cancer
  3. Neutrophil-induced pyroptosis promotes survival in patients with hepatoblastoma.2025Cancer immunology, immunotherapy : CII
  4. Therapeutic targeting de novo purine biosynthesis driven by β-catenin-dependent PPAT upregulation in hepatoblastoma.2025Cell death & disease
  5. A diagnostic model based on transcriptomic analysis reveals inflammation as a potential prognosis factor for hepatoblastoma with hepatocellular carcinoma features.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  6. Integrated analysis identifies CD276 in fibroblasts as a malignancy predictor and regulator of neutrophil infiltration in hepatoblastoma.2025Hepatology communications
  7. TCF3 activates super-enhancer-driven TRIB2 overexpression to suppress ferroptosis and promote hepatoblastoma proliferation.2025Journal of experimental & clinical cancer research : CR
  8. N6-methyadenosine-modified YWHAE mRNA promotes proliferation and inhibits ferroptosis in hepatoblastoma by mediating SLC7A11 expression.2025Oncogene
  9. Whole-genome sequencing and RNA sequencing analysis reveals novel risk genes and differential expression patterns in hepatoblastoma.2024Gene
  10. PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study.2024Hepatology international
  11. N6-methyladenosine modification of LATS2 promotes hepatoblastoma progression by inhibiting ferroptosis through the YAP1/ATF4/PSAT1 axis.2024International journal of biological sciences
  12. Clinical Characteristics and Outcomes of Neonatal Hepatoblastoma: A Single Center Study.2024Journal of pediatric surgery
  13. ACLY-β-catenin axis modulates hepatoblastoma cell proliferation.2023Biochemical and biophysical research communications
  14. Alternative Splicing of lncRNAs From SNHG Family Alters snoRNA Expression and Induces Chemoresistance in Hepatoblastoma.2023Cellular and molecular gastroenterology and hepatology
  15. O-GlcNAcylated LARP1 positively regulated by circCLNS1A facilitates hepatoblastoma progression through DKK4/β-catenin signalling.2023Clinical and translational medicine
  16. Phase separation of YAP mediated by coiled-coil domain promotes hepatoblastoma proliferation via activation of transcription.2023Journal of gastroenterology and hepatology
  17. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.2022Clinical and translational medicine
Chinese-language papers (not in the count)2
  1. [Preliminary efficacy and safety of a dose-intensified C5VD regimen in 24 children with locally advanced hepatoblastoma].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  2. [Preliminary efficacy and safety analysis of modified SIOPEL-4 protocol for newly diagnosed pediatric hepatoblastoma with lung metastases].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)6
  1. Metabolomics study of the metabolic changes in hepatoblastoma cells in response to NTCP/SLC10A1 overexpression.2020The international journal of biochemistry & cell biology
  2. Retrospective Analysis of Childhood Hepatoblastoma in a Single Centre in China.2019Clinical oncology (Royal College of Radiologists (Great Britain))
  3. Characterization of hsa_circ_0000594 as a new biomarker and therapeutic target for hepatoblastoma.2019European review for medical and pharmacological sciences
  4. CircHMGCS1 Promotes Hepatoblastoma Cell Proliferation by Regulating the IGF Signaling Pathway and Glutaminolysis.2019Theranostics
  5. Down-regulation of dishevelled-2 inhibits cell proliferation and invasion in hepatoblastoma.2018Pediatric blood & cancer
  6. [A follow-up report of childhood hepatoblastoma from 74 cases in a single center].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status2
  1. A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyRecruitingNCT04478292Lead sponsorPhase 3Start 2021-03
  2. PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in InfantsCompletedNCT03645655Lead sponsorStart 2018-10

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Chinese-language papers (not in the count)1
  1. [Analysis of 41 cases of non-metastatic Ewing's sarcoma in children].2024Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 11 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
11
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 3320242025: 442025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicinePediatricsSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led11
  1. Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN.2025Cancer medicine
  2. C-reactive protein-to-lymphocyte ratio and hemoglobin-to-red cell distribution width ratio as effective prognostic predictors in pediatric patients with neuroblastoma.2025European journal of pediatrics
  3. DNAJC12 downregulation induces neuroblastoma progression via increased histone H4K5 lactylation.2025Journal of molecular cell biology
  4. Global, regional and national burden of neuroblastoma and other peripheral nervous system tumors, 1990 to 2021 and predictions to 2035: visualizing epidemiological characteristics based on GBD 2021.2025Neoplasia (New York, N.Y.)
  5. Causal Relationship between Sex Hormone-Binding Globulin and Risk of Neuroblastoma: A Bidirectional Two-Sample Mendelian Randomization Study.2024Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  6. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation.2024Journal of experimental & clinical cancer research : CR
  7. Enzyme-Mediated Bioorthogonal Cascade Catalytic Reaction for Metabolism Intervention and Enhanced Ferroptosis on Neuroblastoma.2024Journal of the American Chemical Society
  8. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.2023Cellular oncology (Dordrecht, Netherlands)
  9. Exosomal hsa-piR1089 promotes proliferation and migration in neuroblastoma via targeting KEAP1.2023Pathology, research and practice
  10. Cost-effectiveness analysis of dinutuximab β for the treatment of high-risk neuroblastoma in China.2023Pediatric blood & cancer
  11. MYCN protein stability is a better prognostic indicator in neuroblastoma.2022BMC pediatrics
Earlier papers (2016–2020)6
  1. CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment.2020Cancer immunology, immunotherapy : CII
  2. Krüppel-like factor 9 promotes neuroblastoma differentiation via targeting the sonic hedgehog signaling pathway.2020Pediatric blood & cancer
  3. Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant With a TP53 Germline Mutation: A Case Report and Literature Review.2019Journal of pediatric hematology/oncology
  4. Association of image-defined risk factors, tumor resectability, and prognosis in children with localized neuroblastoma.2019World journal of pediatrics : WJP
  5. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.2017Journal of cancer research and clinical oncology
  6. [Long-term follow-up of neuroblastoma in children less than 18 months of age].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. Study on Sintilimab in Stage IV High Risk NeuroblastomaStatus unknownNCT04412408Lead sponsorEarly phase 1Start 2020-09

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Chinese-language papers (not in the count)1
  1. [Analysis of 41 cases of non-metastatic Ewing's sarcoma in children].2024Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 8 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 3.6%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 2220242025: 222025

9 hospitals in Shanghai for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Registry
    NCT06607419

    Age 1 month to 18 years (registered criteria)

    Led by Shanghai Children's Medical Center; 1 listed hospital as study siteHefei, Shanghai

  2. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT06927466

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenCAR-T & cell therapyStem cell transplant
Departments in papersMedical oncologyPediatrics
Papers it led8
  1. GREM1 deficiency induced bone marrow adipose niche promotes B-cell acute lymphoblastic leukemia disease progression.2025International journal of cancerFree full text
  2. Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review.2025Pharmacogenetics and genomicsFree full text
  3. Histiocytic sarcoma following CAR T-cell therapy: a case report.2024International journal of hematology
  4. TCRαβ-depleted hematopoietic stem cell transplant and third-party CD45RA+ depleted adoptive cell therapy for treatment of post-transplant parvovirus B19 aplastic crisis.2024International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  5. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.2023Journal of translational medicineFree full text
  6. Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia.2023Nature communicationsFree full text
  7. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation.2021BloodFree full text
  8. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.2021Clinical lymphoma, myeloma & leukemia
All its trials on ClinicalTrials.gov, any status3
  1. Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic LeukemiaRecruitingNCT06607419Lead (inferred)Phase 2/Phase 3Start 2024-05
  2. A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.RecruitingNCT06927466Study sitePhase 1Start 2024-09
  3. Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)Active, not recruitingNCT06054113Study sitePhase 2Start 2024-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 5 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025

3 hospitals in Shanghai for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantChildrenImmunosuppressive treatment
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Shanghai for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Molecular genetic characteristics of a family which coinheritance of rare-88 C>G (HBB:c.-138 C>G) β-thalassemia mutation with α-thalassemia and review of the literature].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemiaStatus unknownNCT05773729Study siteN/AStart 2023-09

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 2 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 2.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

4 hospitals in Shanghai for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular AtrophyEnrolling by invitationNCT06888661Study siteEarly phase 1Start 2025-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

6 hospitals in Shanghai for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06539624

    Age 7 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of Medicine; 1 listed hospital as study siteHangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry DiseaseRecruitingNCT06539624Study siteN/AStart 2024-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shanghai for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution

12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06641895

    Age 4 years to 8 years; men only (registered criteria)

    Led by Shanghai Children's Medical CenterShanghai

  2. Recruiting
    Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy
    Phase
    Early phase 1
    Started
    2024-10
    Registry
    NCT06900049

    Age 4 years to 8 years; men only (registered criteria)

    Led by Shanghai Children's Medical CenterShanghai

  3. Recruiting
    Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients
    Phase
    Early phase 1
    Started
    2025-08
    Registry
    NCT07188012

    Age 2 years to 7 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shanghai for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher DiseaseActive, not recruitingNCT06528080Lead (inferred)Early phase 1Start 2024-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 2 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 3.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

6 hospitals in Shanghai for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 2 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

5 hospitals in Shanghai for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海交通大学医学院附属上海儿童医学中心

Shanghai Children's Medical Center

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Fujian Branch of Shanghai Children's Medical Center; Shanghai Children's Medical Centre; SCMC; 上海儿童医学中心

Suggest a correctionDownload the data